GC Biopharma Corp. (KRX:006280)
South Korea flag South Korea · Delayed Price · Currency is KRW
139,200
-900 (-0.64%)
Last updated: Apr 29, 2026, 2:00 PM KST

GC Biopharma Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-4,674-26,280-26,63265,453123,212
Upgrade
Depreciation & Amortization
87,65581,03475,89965,09655,904
Upgrade
Loss (Gain) From Sale of Assets
-40,8672,5112,919-40,657-6,991
Upgrade
Asset Writedown & Restructuring Costs
94,77018,088---
Upgrade
Loss (Gain) From Sale of Investments
9,380-6,665-1,209660333
Upgrade
Loss (Gain) on Equity Investments
-14,58227,46438,43118,099-81,533
Upgrade
Provision & Write-off of Bad Debts
4,3541,0792,7892,2466,980
Upgrade
Other Operating Activities
-11,261-6,5942,64917,11947,052
Upgrade
Change in Accounts Receivable
-27,41352,815-47,09313,219-10,756
Upgrade
Change in Inventory
-124,673-229,626-69,2341,721-14,919
Upgrade
Change in Accounts Payable
19,10112,07722,6894,011-16,463
Upgrade
Change in Other Net Operating Assets
107,67320,637-6,681-27,81323,160
Upgrade
Operating Cash Flow
99,463-53,460-5,473119,154125,979
Upgrade
Operating Cash Flow Growth
----5.42%250.20%
Upgrade
Capital Expenditures
-72,362-31,992-79,087-57,996-102,321
Upgrade
Sale of Property, Plant & Equipment
2,109791.341,3191,540565.21
Upgrade
Cash Acquisitions
-62,261---74,05311,918
Upgrade
Divestitures
-215.13---
Upgrade
Sale (Purchase) of Intangibles
-31,790-9,602-45,914-36,694-21,143
Upgrade
Investment in Securities
-26,828-24,226-25,139-31,332-30,734
Upgrade
Other Investing Activities
957.112,269-1,423-723.710,133
Upgrade
Investing Cash Flow
-186,790-67,894-150,243-205,259-132,077
Upgrade
Short-Term Debt Issued
1,053,0631,221,1401,188,247806,151869,500
Upgrade
Long-Term Debt Issued
168,555279,3875,00030,608209,429
Upgrade
Total Debt Issued
1,221,6181,500,5271,193,247836,7591,078,929
Upgrade
Short-Term Debt Repaid
-1,067,201-1,169,646-1,059,800-721,740-992,600
Upgrade
Long-Term Debt Repaid
-24,142-217,342-9,419-135,590-102,423
Upgrade
Total Debt Repaid
-1,091,343-1,386,988-1,069,219-857,330-1,095,023
Upgrade
Net Debt Issued (Repaid)
130,275113,538124,028-20,571-16,094
Upgrade
Dividends Paid
-18,831-19,532-24,825-23,985-18,511
Upgrade
Other Financing Activities
136.15-160.891,30842,075-6,665
Upgrade
Financing Cash Flow
111,58093,845100,512-2,481-41,270
Upgrade
Foreign Exchange Rate Adjustments
2,556366.22-455.397,8911,141
Upgrade
Net Cash Flow
26,809-27,143-55,660-80,694-46,228
Upgrade
Free Cash Flow
27,101-85,452-84,56061,15823,658
Upgrade
Free Cash Flow Growth
---158.51%-
Upgrade
Free Cash Flow Margin
1.36%-5.09%-5.20%3.57%1.54%
Upgrade
Free Cash Flow Per Share
2374.52-7487.16-7408.975358.562072.84
Upgrade
Cash Interest Paid
38,33238,13924,08019,37813,546
Upgrade
Cash Income Tax Paid
11,1412,46819,03337,34918,867
Upgrade
Levered Free Cash Flow
-2,151-119,077-166,64252,929-10,238
Upgrade
Unlevered Free Cash Flow
29,284-93,803-148,84064,424-2,425
Upgrade
Change in Working Capital
-25,312-144,097-100,319-8,862-18,978
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.